1229236-85-4

Usage

Molecular structure

Consists of a pyridazine core with various substituted aryl and alkyl groups

Medicinal chemistry use

Potential drug candidate for the treatment of certain diseases and disorders

Heterocyclic structure

Contains heteroatoms in the ring structure, contributing to its pharmacological properties

Biological interactions

Specific interactions with biological targets and modulation of cellular processes

Ongoing research

Its role in pharmacology and therapeutic potential is currently under investigation

Clinical applicability

Further studies needed to understand its usefulness in clinical settings.

Upstream product

• 1229236-84-3 (4-chloro-2-fluorophenyl)(6-chloro-2-methyl-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-3-yl)methanol 
• 299411-67-9 2-chloro-1-(4-chloro-2-fluorophenyl)ethan-1-one 
• 175711-83-8 4’-chloro-2’-fluoroacetophenone 
• 1229236-80-9 (4-chloro-2-fluorophenyl)(6-chloro-2-methylimidazo-[1,2-b]pyridazin-3-yl)methanone 
• 1229236-83-2 (4-chloro-2-fluorophenyl)(6-chloro-2-methyl-8-(morpholino-methyl)imidazo[1,2-b]pyridazin-3-yl)methanone 
• 1229236-79-6 (E)-N'-(6-chloropyridazin-3-yl)-N,N-dimethylacetimidamide 
• 1422006-68-5 4-((6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)methyl)morpholine 
• 87417-71-8 4-chloro-1-(chloromethyl)-2-fluorobenzene 
• 14714-18-2 ethyl 6-Chloro-2-methylimidazo[1,2-b]pyridazine-3-carboxylate 

Downstream Products

• 1229236-86-5 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholino-methyl)imidazo[1,2-b]pyridazin-6-amine 
• 1346221-91-7 N-(1-tert-butyl-3-methyl-1H-pyrazol-5-yl)-3-(4-chloro-2-fluorobenzyl)-2-methyl-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine 

Relevant academic research and scientific papers

Development of an alternate synthesis for a key JAK2 inhibitor intermediate via sequential c-h bond functionalization

The development of an alternative synthetic route to a functionalized imidazopyridazine which strategically streamlines the synthesis and avoids a number of problematic reagents is described. Key to the success of this alternative route is the use of two

IMIDAZO[1,2-B]PYRIDAZIN-6-AMINE DERIVATIVES AS KINASE JAK-2 INHIBITORS

A compound represented by the general formula (I) wherein R1represents H or C1-C4 alkyl; R2 represents phenyl substituted with one or two substituents selected from the group consisting of halogen atom and OCsu

Development of a Stepwise Reductive Deoxygenation Process by Ru-Catalysed Homogeneous Ketone Reduction and Pd-Catalysed Hydrogenolysis in the Presence of Cu Salts

A stepwise catalytic reduction of ketone 1 to alcohol 2 and subsequently to aryl(imidazo[1,2-b]pyridazinyl)methane 3 is described, which provides synthetically useful chemoselectivity at acceptably low catalyst loadings. Undesired reactive sites include a

Development and a practical synthesis of the JAK2 inhibitor LY2784544

The route selection and process research and development of a practical synthesis for JAK2 inhibitor LY2784544 is described. The first-generation synthesis route, similar to that used in discovery for derivatization of a benzylic amine moiety, was 14 overall steps and possessed several steps that required extensive development for large-scale production. Route selection considerations led to a modified synthesis that utilized a novel vanadium-catalyzed carbon-carbon bond-forming arylation reaction for incorporation of the key benzylic morpholine moiety. A protecting group used to mask an amino pyrazole unit was modified from PMB to tert-butyl, resulting in a dramatic reduction in the overall length of the route. These two major changes resulted in an eight-step synthesis, which was six steps shorter than the first-generation synthesis. In the pilot plant, the new synthesis was scaled to produce >100 kg of LY2784544 in high yield and purity under GMP conditions. The overall development including the vanadium-catalyzed C-C bond-forming methodology, a ketone reductive deoxygenation, and a palladium-catalyzed amination is described.

AMINO PYRAZOLE COMPOUND

The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.